When US health officials meet next month to reconsider a list of contested peptide drugs, they will hear from a panel that includes more than a half-dozen members with deep financial ties to the booming industry built around the compounds, according to the FDA's release of participants for the meeting — a roster that has drawn scrutiny over potential conflicts of interest.
The compounds at issue are peptides, short chains of amino acids marketed for everything from weight loss and muscle building to anti-aging and recovery. Health Secretary Robert F. Kennedy Jr. has called himself a 'big fan' and has pushed to broaden access, but FDA career scientists have signaled that there is not enough evidence to clear certain peptides for production by compounding pharmacies, setting up a clash between the department's political leadership and its technical staff.
In February, Kennedy announced that roughly 14 of the 19 peptides on the FDA's Category 2 restricted compounding list would be moved back to Category 1, a designation governing whether licensed compounding pharmacies may legally prepare them. The change was slated to take effect in April, with the agency's Pharmacy Compounding Advisory Committee scheduled to formally review the substances at a meeting on July 23 and 24.
Crucially, moving a peptide from Category 2 to Category 1 is a regulatory reclassification, not an FDA approval. It would permit compounding pharmacies to prepare the substances, but it does not mean the agency has found them safe and effective as drugs in the way it evaluates approved medicines — a distinction that has fueled confusion in the wellness market and concern among regulators.
The composition of the July panel has become a flashpoint. Among the members is Dr. Haleem Mohammed, who runs clinics in Florida that sell injections of peptides, vitamins, testosterone and weight-loss medications, alongside other panelists who operate clinics, online businesses or pharmacies specializing in the compounds. Critics say seating practitioners who profit from peptides to advise on loosening restrictions undermines the independence the advisory process is meant to provide.
Scientists and patient-safety advocates point to specific risks with compounded peptides, including immunogenicity, the potential for the body to mount immune reactions; aggregation, in which protein molecules clump; sterility concerns in preparation; and a general lack of rigorous clinical evidence. Those issues are central to why the compounds were restricted in the first place, and why FDA staff have been cautious about easing the rules.
The advisory committee's recommendations are not binding, but they carry weight and shape the public record the FDA relies on. With Kennedy's department having already signaled where it wants to land and the panel weighted toward industry-aligned voices, the July meeting will be closely watched as a measure of whether the agency's expert review still operates as an independent guardrail or as cover for a decision driven from the top.